Allarity Therapeutics, Inc. 8-K

What Happened
Allarity Therapeutics, Inc. announced on June 22, 2026 (8-K filing) that it presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress held June 17–19, 2026, in Copenhagen, Denmark. The company attached a press release dated June 18, 2026, summarizing the presentation.

Key Details

• Filing date: June 22, 2026 (Form 8-K, Item 8.01 Other Events).
• Event: Trial-in-progress poster presented at ESMO Gynaecological Cancers Congress, Copenhagen, Denmark (June 17–19, 2026).
• Press release: Attached as Exhibit 99.1, dated June 18, 2026.
• No financial results, executive changes, or other regulatory actions were reported in this 8-K.

Why It Matters
This filing notifies investors that Allarity is actively communicating clinical development progress to the oncology community, which can provide visibility into its research pipeline. The 8-K is informational—there were no earnings, personnel changes, or financial disclosures tied to this announcement. Investors tracking Allarity’s clinical milestones should note the presentation and review the attached press release for details on the trial status.